Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|August 1, 2006
- Pharmaceutical Executive-08-01-2006
- Volume 0
- Issue 0
Time Machine
Think you've been around a long time? When's the last time your company gave a doctor a cigarette lighter with your logo on it? Put any corks in medicine bottles lately? Can you remember the last hero shot of a pharma CEO on the cover of Time? We can. And we have the artifacts to prove it...
Advertisement
Articles in this issue
about 20 years ago
Getting Betterabout 20 years ago
States Curb Marketingabout 20 years ago
From the Editor: Take Your Seatabout 20 years ago
Viewpoint: In Your Wordsabout 20 years ago
Quiz Answersabout 20 years ago
Introduction: Pharm Exec at 25about 20 years ago
How Far We've ComeAdvertisement
Related to this article
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Rebuilding Clinical Data Workflows for the AI Era
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5